Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioTransplant obtains United States patent.


BioTransplant, Inc. (Charlestown, MA) has patented a composition and method for determining the levels of specific immune responsiveness to a glycoprotein glycoprotein (glī'kōprō`tēn), organic compound composed of both a protein and a carbohydrate joined together in covalent chemical linkage.  in an individual being treated therewith there·with  
adv.
1. With that, this, or it.

2. In addition to that.

3. Archaic Immediately thereafter.

Adv. 1.
 by (i) contacting a body fluid sample obtained from the individual prior to glycoprotein treatment with glycoprotein that has been modified to have an oxidized oxidized

having been modified by the process of oxidation.


oxidized cellulose
see absorbable cellulose.
 carbohydrate portion; (ii) contacting a body fluid sample obtained from the individual subsequent to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and (iii) observing the degree of difference in the specific immune response immune response
n.
An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes.
 to the oxidized glycoprotein in the pre- and post-treatment samples. (US 5856106)
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Jun 1, 1999
Words:105
Previous Article:Takeda obtains United States patent.
Next Article:PPL Therapeutics develops technique for birth of transgenic sheep with 'targeted' gene.
Topics:



Related Articles
United States companies are ignoring technology assets with a potential commercial value well in excess of $115 billion, according to a recently...
BioTransplant receives Orphan Drug designation from FDA for MEDI-507 antibody.
TKT updates status of erythropoietin litigation.
PPL successfully clones 5 piglets; experts say event could presage new era in xenotransplantation.
BUSINESS BRIEFS Novartis Pharma, BioTransplant join to create new xenotransplantation company.
Hollis-Eden expands its intellectual property position and acquires minority interest in Aeson Therapeutics.
UK government advisory panel has serious doubts about prospects for successful xenotransplantation.
BioTransplant, Novartis say newly named Immerge BioTherapeutics began operations January 2.
Infigen terminates agreement with Pharming Holding.
BIOTRANSPLANT REPORTS 2ND QTR '02 NET LOSS OF $24.08 MILLION.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles